Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Evaluate the Efficacy and Safety of GS-6624 in Adult Subjects With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

NCT01369498 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01369498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01369498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Evaluate the Efficacy and Safety of GS-6624 in Adult Subjects With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2011
Completion date
September 24, 2014
Enrollment
54 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis